vs
百特国际（BAX）与Revvity（RVTY）财务数据对比。点击上方公司名可切换其他公司
百特国际的季度营收约是Revvity的3.9倍（$3.0B vs $772.1M），Revvity净利率更高（12.7% vs -37.9%，领先50.7%），百特国际同比增速更快（458.0% vs 5.9%），过去两年Revvity的营收复合增速更高（9.0% vs -9.0%）
百特国际是总部位于美国伊利诺伊州迪尔菲尔德的跨国医疗健康企业，业务布局覆盖全球众多市场，专注于研发、生产及销售各类医疗相关产品与解决方案，为全球医疗机构和患者提供专业可靠的医疗支持。
Revvity是一家美国生命科学与诊断领域企业，主要服务制药、生物技术行业客户，重点围绕细胞治疗、基因治疗等前沿技术领域提供相关产品与解决方案，其前身为业务布局多元的老牌企业珀金埃尔默。
BAX vs RVTY — 直观对比
营收规模更大
BAX
是对方的3.9倍
$772.1M
营收增速更快
BAX
高出452.1%
5.9%
净利率更高
RVTY
高出50.7%
-37.9%
两年增速更快
RVTY
近两年复合增速
-9.0%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $3.0B | $772.1M |
| 净利润 | $-1.1B | $98.4M |
| 毛利率 | 19.4% | — |
| 营业利润率 | -24.5% | 14.5% |
| 净利率 | -37.9% | 12.7% |
| 营收同比 | 458.0% | 5.9% |
| 净利润同比 | -120.3% | 3.9% |
| 每股收益（稀释后） | $-2.21 | $0.86 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BAXRVTY
| Q4 25 | $3.0B | $772.1M | ||
| Q3 25 | $2.8B | $698.9M | ||
| Q2 25 | $2.8B | $720.3M | ||
| Q1 25 | $2.6B | $664.8M | ||
| Q4 24 | $533.0M | $729.4M | ||
| Q3 24 | $2.7B | $684.0M | ||
| Q2 24 | $3.8B | $691.7M | ||
| Q1 24 | $3.6B | $649.9M |
净利润BAXRVTY
| Q4 25 | $-1.1B | $98.4M | ||
| Q3 25 | $-46.0M | $46.7M | ||
| Q2 25 | $91.0M | $53.9M | ||
| Q1 25 | $126.0M | $42.2M | ||
| Q4 24 | $-512.0M | $94.6M | ||
| Q3 24 | $140.0M | $94.4M | ||
| Q2 24 | $-314.0M | $55.4M | ||
| Q1 24 | $37.0M | $26.0M |
毛利率BAXRVTY
| Q4 25 | 19.4% | — | ||
| Q3 25 | 33.5% | 53.6% | ||
| Q2 25 | 35.3% | 54.5% | ||
| Q1 25 | 32.8% | 56.5% | ||
| Q4 24 | 25.0% | — | ||
| Q3 24 | 38.3% | 56.3% | ||
| Q2 24 | 37.5% | 55.7% | ||
| Q1 24 | 38.6% | 54.6% |
营业利润率BAXRVTY
| Q4 25 | -24.5% | 14.5% | ||
| Q3 25 | 6.1% | 11.7% | ||
| Q2 25 | 6.8% | 12.6% | ||
| Q1 25 | 2.2% | 10.9% | ||
| Q4 24 | -25.5% | 16.3% | ||
| Q3 24 | 5.7% | 14.3% | ||
| Q2 24 | -5.0% | 12.4% | ||
| Q1 24 | 5.2% | 6.8% |
净利率BAXRVTY
| Q4 25 | -37.9% | 12.7% | ||
| Q3 25 | -1.6% | 6.7% | ||
| Q2 25 | 3.2% | 7.5% | ||
| Q1 25 | 4.8% | 6.4% | ||
| Q4 24 | -96.1% | 13.0% | ||
| Q3 24 | 5.2% | 13.8% | ||
| Q2 24 | -8.2% | 8.0% | ||
| Q1 24 | 1.0% | 4.0% |
每股收益（稀释后）BAXRVTY
| Q4 25 | $-2.21 | $0.86 | ||
| Q3 25 | $-0.09 | $0.40 | ||
| Q2 25 | $0.18 | $0.46 | ||
| Q1 25 | $0.25 | $0.35 | ||
| Q4 24 | $-0.99 | $0.77 | ||
| Q3 24 | $0.27 | $0.77 | ||
| Q2 24 | $-0.62 | $0.45 | ||
| Q1 24 | $0.07 | $0.21 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $2.0B | $919.9M |
| 总债务越低越好 | $9.5B | — |
| 股东权益账面价值 | $6.1B | $7.3B |
| 总资产 | $20.1B | $12.2B |
| 负债/权益比越低杠杆越低 | 1.55× | — |
8季度趋势，按日历期对齐
现金及短期投资BAXRVTY
| Q4 25 | $2.0B | $919.9M | ||
| Q3 25 | $1.7B | $931.4M | ||
| Q2 25 | $1.7B | $991.8M | ||
| Q1 25 | $2.3B | $1.1B | ||
| Q4 24 | $1.8B | $1.2B | ||
| Q3 24 | $1.4B | $1.2B | ||
| Q2 24 | $2.1B | $2.0B | ||
| Q1 24 | $3.0B | $1.7B |
总债务BAXRVTY
| Q4 25 | $9.5B | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $10.4B | — | ||
| Q3 24 | $10.4B | — | ||
| Q2 24 | $10.4B | — | ||
| Q1 24 | $11.1B | — |
股东权益BAXRVTY
| Q4 25 | $6.1B | $7.3B | ||
| Q3 25 | $7.2B | $7.4B | ||
| Q2 25 | $7.3B | $7.6B | ||
| Q1 25 | $7.1B | $7.6B | ||
| Q4 24 | $7.0B | $7.7B | ||
| Q3 24 | $7.9B | $7.9B | ||
| Q2 24 | $7.6B | $7.9B | ||
| Q1 24 | $8.2B | $7.8B |
总资产BAXRVTY
| Q4 25 | $20.1B | $12.2B | ||
| Q3 25 | $21.1B | $12.1B | ||
| Q2 25 | $21.0B | $12.4B | ||
| Q1 25 | $21.3B | $12.4B | ||
| Q4 24 | $25.8B | $12.4B | ||
| Q3 24 | $26.7B | $12.8B | ||
| Q2 24 | $26.3B | $13.4B | ||
| Q1 24 | $27.8B | $13.4B |
负债/权益比BAXRVTY
| Q4 25 | 1.55× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 1.49× | — | ||
| Q3 24 | 1.33× | — | ||
| Q2 24 | 1.37× | — | ||
| Q1 24 | 1.36× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $584.0M | $182.0M |
| 自由现金流经营现金流 - 资本支出 | — | $161.8M |
| 自由现金流率自由现金流/营收 | — | 21.0% |
| 资本支出强度资本支出/营收 | — | 2.6% |
| 现金转化率经营现金流/净利润 | — | 1.85× |
| 过去12个月自由现金流最近4个季度 | — | $509.4M |
8季度趋势，按日历期对齐
经营现金流BAXRVTY
| Q4 25 | $584.0M | $182.0M | ||
| Q3 25 | $237.0M | $138.5M | ||
| Q2 25 | $217.0M | $134.3M | ||
| Q1 25 | $-193.0M | $128.2M | ||
| Q4 24 | $488.0M | $174.2M | ||
| Q3 24 | $253.0M | $147.9M | ||
| Q2 24 | $115.0M | $158.6M | ||
| Q1 24 | $163.0M | $147.6M |
自由现金流BAXRVTY
| Q4 25 | — | $161.8M | ||
| Q3 25 | — | $120.0M | ||
| Q2 25 | — | $115.5M | ||
| Q1 25 | — | $112.2M | ||
| Q4 24 | — | $149.8M | ||
| Q3 24 | — | $125.6M | ||
| Q2 24 | — | $136.6M | ||
| Q1 24 | — | $129.7M |
自由现金流率BAXRVTY
| Q4 25 | — | 21.0% | ||
| Q3 25 | — | 17.2% | ||
| Q2 25 | — | 16.0% | ||
| Q1 25 | — | 16.9% | ||
| Q4 24 | — | 20.5% | ||
| Q3 24 | — | 18.4% | ||
| Q2 24 | — | 19.7% | ||
| Q1 24 | — | 20.0% |
资本支出强度BAXRVTY
| Q4 25 | — | 2.6% | ||
| Q3 25 | — | 2.6% | ||
| Q2 25 | — | 2.6% | ||
| Q1 25 | — | 2.4% | ||
| Q4 24 | — | 3.4% | ||
| Q3 24 | — | 3.3% | ||
| Q2 24 | — | 3.2% | ||
| Q1 24 | — | 2.7% |
现金转化率BAXRVTY
| Q4 25 | — | 1.85× | ||
| Q3 25 | — | 2.97× | ||
| Q2 25 | 2.38× | 2.49× | ||
| Q1 25 | -1.53× | 3.03× | ||
| Q4 24 | — | 1.84× | ||
| Q3 24 | 1.81× | 1.57× | ||
| Q2 24 | — | 2.87× | ||
| Q1 24 | 4.41× | 5.67× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BAX
| Other | $1.5B | 51% |
| Infusion Therapies And Technologies | $543.0M | 18% |
| Pharmaceutical Compounding | $316.0M | 11% |
| Front Line Care | $219.0M | 7% |
| Injectables And Anesthesia | $190.0M | 6% |
| Advanced Surgery | $177.0M | 6% |
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
